60
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Background

          Since 2014, England has seen increased scarlet fever activity unprecedented in modern times. In 2016, England's scarlet fever seasonal rise coincided with an unexpected elevation in invasive Streptococcus pyogenes infections. We describe the molecular epidemiological investigation of these events.

          Methods

          We analysed changes in S pyogenes emm genotypes, and notifications of scarlet fever and invasive disease in 2014–16 using regional (northwest London) and national (England and Wales) data. Genomes of 135 non-invasive and 552 invasive emm1 isolates from 2009–16 were analysed and compared with 2800 global emm1 sequences. Transcript and protein expression of streptococcal pyrogenic exotoxin A (SpeA; also known as scarlet fever or erythrogenic toxin A) in sequenced, non-invasive emm1 isolates was quantified by real-time PCR and western blot analyses.

          Findings

          Coincident with national increases in scarlet fever and invasive disease notifications, emm1 S pyogenes upper respiratory tract isolates increased significantly in northwest London in the March to May period, from five (5%) of 96 isolates in 2014, to 28 (19%) of 147 isolates in 2015 (p=0·0021 vs 2014 values), to 47 (33%) of 144 in 2016 (p=0·0080 vs 2015 values). Similarly, invasive emm1 isolates collected nationally in the same period increased from 183 (31%) of 587 in 2015 to 267 (42%) of 637 in 2016 (p<0·0001). Sequences of emm1 isolates from 2009–16 showed emergence of a new emm1 lineage (designated M1 UK)—with overlap of pharyngitis, scarlet fever, and invasive M1 UK strains—which could be genotypically distinguished from pandemic emm1 isolates (M1 global) by 27 single-nucleotide polymorphisms. Median SpeA protein concentration in supernatant was nine-times higher among M1 UK isolates (190·2 ng/mL [IQR 168·9–200·4]; n=10) than M1 global isolates (20·9 ng/mL [0·0–27·3]; n=10; p<0·0001). M1 UK expanded nationally to represent 252 (84%) of all 299 emm1 genomes in 2016. Phylogenetic analysis of published datasets identified single M1 UK isolates in Denmark and the USA.

          Interpretation

          A dominant new emm1 S pyogenes lineage characterised by increased SpeA production has emerged during increased S pyogenes activity in England. The expanded reservoir of M1 UK and recognised invasive potential of emm1 S pyogenes provide plausible explanation for the increased incidence of invasive disease, and rationale for global surveillance.

          Funding

          UK Medical Research Council, UK National Institute for Health Research, Wellcome Trust, Rosetrees Trust, Stoneygate Trust.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Genome-Wide Analysis of Group A Streptococci Reveals a Mutation That Modulates Global Phenotype and Disease Specificity

          Introduction Bacterial pathogens have long been recognized to undergo phenotypic variation (reviewed in [1]). Historically, interest in this phenomenon has been fueled by the observation that phenotypic variants can differ in pathogenesis characteristics, such as increased or decreased virulence, or adaptation to a particular anatomic site. Extensive work has been directed at elucidating the molecular genetic events that contribute to phenotypic variation, with antigenic variation being the best-studied category. With few exceptions, most studies have focused on analysis of a distinct phenotype such as adhesin production or lipooligosaccharide structural modification. Several molecular mechanisms have been documented to contribute to phenotypic variation, the most common being slipped-strand mispairing events that result in phase-variable expression of the associated gene [1]. The group A streptococci (GAS) cause many distinct human infections [2]. Disease manifestations range from mild infections such as pharyngitis (“strep throat”) and impetigo, to extensive tissue destruction in the case of necrotizing fasciitis (the “flesh-eating” syndrome). Postinfection sequelae such as rheumatic fever and glomerulonephritis can also occur. The mechanisms that enable GAS to cause diverse diseases are unknown, although both bacterial and host-specific components are thought to be involved [3]. Associated morphologic and virulence variation in GAS has been known for almost 90 y [4,5]. Classic studies identified GAS phenotypic variation during invasive and upper respiratory tract infections [4,6]. More recently, correlations have been reported between the source of GAS clinical isolates and their ability to invade human epithelial cells or secrete high concentrations of virulence factors such as streptococcal pyrogenic exotoxin A, B, and C (SpeA, SpeB, and SpeC), or streptolysin O (SLO) [7–9]. Such correlations have been observed for multiple GAS serotypes, including clonal contemporary serotype M1 GAS [10]. The idea that GAS phenotypic heterogeneity contributes to distinct disease manifestations is supported by the identification of inherited alterations in virulence factor production when GAS is passaged in human blood ex vivo or through mice [5,11–14]. Virulence factor production by GAS is regulated by stand-alone transcription factors and two-component signal transduction systems (TCSs) [15]. Thirteen TCSs have been described in GAS, of which the CovRS system (also known as CsrRS) is the best characterized. CovRS is a negative regulatory TCS that directly or indirectly influences expression of 10% to 15% of GAS genes, including several virulence factors [16–21]. Despite these advances, we have an imprecise understanding of the contribution of phenotypic variation to host–pathogen interactions in GAS, and the molecular mechanism(s) controlling this heterogeneity. Recently, genome-wide investigative strategies have been used successfully to provide new information about GAS population genetics, evolution, and pathogenesis [22]. Inasmuch as phenotypic variation in GAS may be a key component of the pathogen life cycle, we chose to investigate this phenomenon using genome-wide analytic strategies, including transcriptome profiling and genome resequencing. Here we report genome, transcriptome, and partial secretome differences that distinguish GAS isolated from invasive and pharyngeal infections and permit a heretofore unattainable understanding of phenotypic variation in a microbial pathogen. Results Transcriptome-Based Grouping of Serotype M1 GAS Strains The transcriptomes of nine contemporary (post-1987) serotype M1 GAS strains grown to early exponential phase in Todd-Hewitt broth with yeast extract (THY) were analyzed with an Affymetrix expression microarray. These nine strains included six from patients with pharyngitis and three from invasive disease episodes and were selected from approximately 2,000 genetically characterized serotype M1 strains [10]. Two very distinct transcriptome clusters were identified based on analysis of the microarray data (Figure 1A). The three invasive isolates formed one cluster termed an invasive transcriptome profile (ITP), and the six pharyngitis isolates formed a second cluster termed a pharyngeal transcriptome profile (PTP). The data imply that GAS strains cultured from patients with pharyngeal and invasive disease have distinct transcriptomes, which are retained upon in vitro growth. Analysis of differential gene expression between the two transcriptome profiles identified 89 genes that were statistically significant (t-test followed by a false discovery rate correction, Q 2-fold by ITP strains are colored red. Virulence factors/regulators transcribed >2-fold by PTP strains are colored blue. The emm gene, encoding the important virulence factor M protein, is highlighted yellow for reference. (155 KB PPT) Click here for additional data file. Figure S2 Schematic of Experiment Leading to Isolation of Mouse-Passaged GAS Derivatives PTP GAS (blue box, nonmucoid) or ITP GAS (red box, mucoid) were injected subcutaneously into mice. Five days after infection mice were euthanized and GAS isolated from spleens and skin lesions. ITP GAS were isolated from the spleens and skin lesions of all infected mice. GAS recovered from skin lesions of mice infected with PTP GAS had an approximately 1:1 ratio of ITP to PTP GAS. (9.2 MB PPT) Click here for additional data file. Figure S3 ITP Strains Secrete Increased NADase Activity Compared to PTP Strains NADase titers are shown on the y-axis, with different GAS strains shown on the x-axis. Color coding is as described for Figure 2B. The experiment was performed in duplicate and results identical to those shown were obtained on both occasions. NEG, negative controls. (29 KB PPT) Click here for additional data file. Figure S4 Correlation of Microarray Data between ITP/PTP GAS Isolated from Clinical Sources and following Mouse Passage The fold change in transcript levels (ITP relative to PTP) of 24 virulence-related genes from the clinical GAS microarray (Figure 1) and the mouse-passaged GAS microarray (Figure 2) were log-transformed and plotted against each other to evaluate their correlation. (44 KB PPT) Click here for additional data file. Protocol S1 Comparative Genomic Resequencing (27 KB DOC) Click here for additional data file. Table S1 Serotype M1 Group A Streptococcus Isolates Studied (95 KB DOC) Click here for additional data file. Accession Numbers Expression microarray data have been deposited at the Gene Expression Omnibus database at National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo) and are accessible through accession numbers GSE3899 and GSE3900. The GenBank (http://www.ncbi.nlm.nih.gov) accession number for the whole genome sequence of strain MGAS5005 is CP000017.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A.

            There is concern that group A streptococci, which have caused less serious infections in developed countries in recent decades, may be acquiring greater virulence. We describe 20 patients from the Rocky Mountain region who had group A streptococcal infections from 1986 to 1988 that were remarkable for the severity of local tissue destruction and life-threatening systemic toxicity. Among the 20 patients (median age, 36), necrotizing fasciitis with or without myositis was the most common soft-tissue infection (55 percent). Nineteen patients (95 percent) had shock, 16 (80 percent) had renal impairment, and 11 (55 percent) had acute respiratory distress syndrome. The mortality rate was 30 percent. All patients but 1 had positive tissue cultures for Streptococcus pyogenes; 12 had positive blood cultures. Most of the patients had no underlying disease; 2 used intravenous drugs. Strains of group A beta-hemolytic streptococci isolated from 10 patients were not of a single M or T type; however, 8 of the 10 strains produced pyrogenic exotoxin A (scarlet fever toxin A, a classic erythrogenic toxin), which has rarely been observed in recent years. From our study of this cluster of severe streptococcal infections with a toxic shock-like syndrome, we conclude that in our region, more virulent group A streptococci have reappeared that produce the pyrogenic toxin A associated with scarlet fever.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences.

              We sequenced the genomes of 3,615 strains of serotype Emm protein 1 (M1) group A Streptococcus to unravel the nature and timing of molecular events contributing to the emergence, dissemination, and genetic diversification of an unusually virulent clone that now causes epidemic human infections worldwide. We discovered that the contemporary epidemic clone emerged in stepwise fashion from a precursor cell that first contained the phage encoding an extracellular DNase virulence factor (streptococcal DNase D2, SdaD2) and subsequently acquired the phage encoding the SpeA1 variant of the streptococcal pyrogenic exotoxin A superantigen. The SpeA2 toxin variant evolved from SpeA1 by a single-nucleotide change in the M1 progenitor strain before acquisition by horizontal gene transfer of a large chromosomal region encoding secreted toxins NAD(+)-glycohydrolase and streptolysin O. Acquisition of this 36-kb region in the early 1980s into just one cell containing the phage-encoded sdaD2 and speA2 genes was the final major molecular event preceding the emergence and rapid intercontinental spread of the contemporary epidemic clone. Thus, we resolve a decades-old controversy about the type and sequence of genomic alterations that produced this explosive epidemic. Analysis of comprehensive, population-based contemporary invasive strains from seven countries identified strong patterns of temporal population structure. Compared with a preepidemic reference strain, the contemporary clone is significantly more virulent in nonhuman primate models of pharyngitis and necrotizing fasciitis. A key finding is that the molecular evolutionary events transpiring in just one bacterial cell ultimately have produced millions of human infections worldwide.
                Bookmark

                Author and article information

                Contributors
                Journal
                Lancet Infect Dis
                Lancet Infect Dis
                The Lancet. Infectious Diseases
                Elsevier Science ;, The Lancet Pub. Group
                1473-3099
                1474-4457
                1 November 2019
                November 2019
                : 19
                : 11
                : 1209-1218
                Affiliations
                [a ]Department of Infectious Diseases and Medical Research Council Centre for Molecular Bacteriology & Infection, Imperial College London, London, UK
                [b ]Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK
                [c ]Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, National Institute for Health Research, Imperial College London, London, UK
                [d ]Molecular Biology & Biotechnology, University of Sheffield, Sheffield, UK
                [e ]North-West London Health Protection Team, London Public Health England Centre, Public Health England, London, UK
                [f ]National Infection Service, Public Health England, London, UK
                [g ]Wellcome Sanger Institute, Cambridge, UK
                Author notes
                [* ]Correspondence to: Prof Shiranee Sriskandan, Department of Infectious Diseases and Medical Research Council Centre for Molecular Bacteriology & Infection, Imperial College London, London W12 0NN, UK s.sriskandan@ 123456imperial.ac.uk
                [†]

                Joint first authors

                Article
                S1473-3099(19)30446-3
                10.1016/S1473-3099(19)30446-3
                6838661
                31519541
                93e79755-d87f-48b2-ba23-4e7f9e93fb05
                © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                Categories
                Article

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article